MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
62.91
-0.98 (-1.53%)
Sep 18, 2026, 4:00 PM EDT - Market closed
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,655,429
Market Cap
3.03B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Sep 30, 2024 | 38 | 11 | 40.74% |
| Jun 30, 2024 | 36 | - | - |
| Mar 31, 2024 | 28 | - | - |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Zai Lab | 1,784 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 289 |
| Immunome | 247 |
| uniQure | 221 |
MBX News
- 3 days ago - MBX Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 10 days ago - MBX Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - GlobeNewsWire
- 23 days ago - MBX Biosciences doses first patient in oPTimize clinical trial - TheFly
- 23 days ago - MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism - GlobeNewsWire
- 4 weeks ago - MBX Biosciences reinstated with an Overweight at JPMorgan - TheFly
- 5 weeks ago - MBX Biosciences price target raised to $88 from $70 at Truist - TheFly
- 6 weeks ago - MBX Biosciences price target raised to $88 from $70 at Barclays - TheFly